Vincerx Pharma, Inc.: Nasdaq/NYSE listing notice — Vincerx Pharma receives Nasdaq bid price deficiency notice

Vincerx Pharma, Inc.

Closing bid price below $1.00 for 30 consecutive business days triggers Nasdaq notice.
Company has 180 calendar days to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, Company may be eligible for an additional 180-day compliance period.
Reverse stock split is among options being considered to remedy the deficiency.
Failure to regain compliance could result in delisting from Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vincerx Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 14, 2023, Vincerx Pharma, Inc. (“Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “VINC.” In accordance with Nasdaq Listing R

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-236156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.